# Federated Investors

> Federated Investors is a VC fund backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Pittsburgh, United States
- Total investments: 7
- Last investment: Jul 2016
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/federated-investors-inc
- X (Twitter): http://twitter.com/federatednews
- Website: http://www.federatedinvestors.com/FII/home.do
- Facebook: http://www.facebook.com/pages/Federated-Investors/106067139424578

Federated Investors is a VC fund in Pittsburgh focused on Health Care and Biotechnology. Since 1955, millions of investors in the United States and around the globe have relied on Federated Investors, Inc. (NYSE: FII) for world-class investment management. Federated has grown to become one of the nation's largest investment managers with $367.2 billion in assets under management.Federated has honed its disciplined investmentprocess over a half-century to deliver style-consistent investment products, including 123 domestic and international equity, fixed-income and money market funds, as well as a variety of separately managed accounts. Federated's diversified product line is distributed through more than 8,400 financial intermediaries and institutions who assist investors in meeting their unique objectives.

## Contacts

5 contacts available for Federated Investors. Shizune tracks 1 team members at Federated Investors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/federated-investors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Biotechnology | 2 | 29% |
| Pharmaceutical | 2 | 29% |
| Retail | 1 | 14% |
| Medical | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Series E | 1 | 14% |
| Series F | 1 | 14% |
| Funding Round | 1 | 14% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Israel | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ed Selker | Director, Enterprise Data Operations | 0 | https://shizune.co/investors/profile/ed-selker |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SteadyMed Therapeutics | SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of thedevice will be tailored in accordance with the requirements of the company's partners. | $32M | Post-IPO Equity | Jul 30, 2016 |  |
| SteadyMed Therapeutics | SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of thedevice will be tailored in accordance with the requirements of the company's partners. | $12.2M |  | Feb 03, 2015 |  |
| Sanarus Medical | Sanarus Medical, Inc. develops and markets minimally invasive devices for the diagnosis and treatment of breast tumors. It offers Visica treatment system for cryoablation of breast fibroadenomas; Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and ImarC tissue marker system, aline of breast tissue markers that are visible under imaging modalities. The company was founded in 1999 and is headquartered in Pleasanton, California. | $15M | Series E | Feb 20, 2007 |  |
| Sanarus Medical | Sanarus Medical, Inc. develops and markets minimally invasive devices for the diagnosis and treatment of breast tumors. It offers Visica treatment system for cryoablation of breast fibroadenomas; Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and ImarC tissue marker system, aline of breast tissue markers that are visible under imaging modalities. The company was founded in 1999 and is headquartered in Pleasanton, California. | $19.1M | Series C | Nov 13, 2003 |  |
| Acadia Pharmaceuticals Inc. | Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. TheCompany is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study. | $25M | Series F | Mar 31, 2003 |  |
| Sanarus Medical | Sanarus Medical, Inc. develops and markets minimally invasive devices for the diagnosis and treatment of breast tumors. It offers Visica treatment system for cryoablation of breast fibroadenomas; Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and ImarC tissue marker system, aline of breast tissue markers that are visible under imaging modalities. The company was founded in 1999 and is headquartered in Pleasanton, California. | $13.8M | Series B | Jul 24, 2001 |  |
| ROXY.com | ROXY.com a consumer electronics retailer. | $25M | Private Equity | May 04, 2000 |  |

7 of 7 investments shown.

## Co-investors
- [Forward Ventures](https://shizune.co/investors/profile/forward-ventures) — VC Fund, 3 deals together
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 3 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 2 deals together
- [Channel Medical Partners](https://shizune.co/investors/profile/channel-medical-partners) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Technology Funding](https://shizune.co/investors/profile/technology-funding1) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Federated Investors invest in?

Federated Investors invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Federated Investors?

Public channels for Federated Investors include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Federated Investors?

The team at Federated Investors includes Ed Selker (Director, Enterprise Data Operations). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co